Nplate
FDA Changes Requirements for Two Blood Drugs »
"The approval of changes to the Risk Evaluation and Mitigation Strategies (REMS) for both Nplate (romiplostim) and Promacta (eltrombopag) was announced by the U.S. Food and Drug Administration.
An FDA-initiated review of the current in"...
Read the FDA Changes Requirements for Two Blood Drugs article »
Nplate
Nplate Consumer (continued)
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use.
This document does not contain all possible interactions. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: This medication must be used under close medical supervision so your blood counts can be monitored. Laboratory and/or medical tests (such as blood and platelet counts) should be performed before you start treatment, weekly when first starting, and then monthly to monitor your progress or check for side effects. Consult your doctor for more details.
MISSED DOSE: If you miss a dose, contact your doctor or pharmacist immediately to establish a new dosing schedule.
STORAGE: Not applicable. This medication is given in a clinic or doctor's office and will not be stored at home.
MEDICAL ALERT: Your condition can cause complications in a medical emergency. For enrollment information call MedicAlert at 1-800-854-1166 (USA) or 1-800-668-1507 (Canada).
Information last revised October 2010. Copyright(c) 2010 First Databank, Inc.
Additional Nplate Information
Nplate - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.






